No'Rebound' Arterial Effect Seen With HRT Cessation No'Rebound' Arterial Effect Seen With HRT Cessation
Three years after ending hormone replacement therapy for menopause symptoms, women show no significant differences in measures of atherosclerosis versus those who had taken placebo.Medscape Medical News
Conclusions: Consistent with previous literature, our analysis found that type 2 cancer is more common in non-white, older, and less obese patients and associated with higher mortality and recurrence. However, inconsistent with previous literature, we found no association between type 2 cancer and diabetes mellitus or use of HRT. These factors should be considered when approaching patients with endometrial cancer.Gynecol Obstet Invest
Breast cancer is the most prevalent cancer in the U.S., affecting almost 85 of every 100,000 Americans, according to recent data from the World Health Organization’s International Agency for Research on Cancer (IARC). Around the globe, 627,000 people are projected to die from breast cancer this year alone. The silver lining is that with early detection and proper care, breast cancer is among the most treatable forms of the disease. In the U.S., breast cancer deaths dropped by 40% between 1989 and 2015, thanks to better screening and access to care — but a large body of research suggests that widespread adoption...
Hormone replacement therapy (HRT) is not associated with cognitive decline when women have recently started the menopause or do not have diabetes, according to US researchers.
Abstract There is increasing evidence that menopause is associated with the progression and severity of non-alcoholic fatty liver disease (NAFLD). Estrogen deficiency worsens non-alcoholic steatohepatitis (NASH) in mice models with fatty liver. The prevalence of NAFLD seems to be higher in postmenopausal compared with premenopausal women. Although more data are needed, lower serum estradiol levels are associated with NASH in postmenopausal women. Apart from estrogen deficiency, relative androgen excess and decrease in sex hormone-binding protein are observed in postmenopausal women. These hormonal changes seem to ...
Conclusions Supplementation with soy protein with isoflavones for 6 months significantly improved CVR markers and calculated CVR at 6 months during early menopause compared to soy protein without isoflavones. ISRCTN registry ISRCTN34051237.
Taking hormone replacement therapy during menopause may improve the structure and function of women's hearts, potentially lowering their risk of heart disease, say UK investigators.Medscape Medical News
ConclusionMultifactorial mechanisms lead to UUI and vascular risk factors may contribute to the pathogenesis of bladder overactivity in addition to higher BMI. Severe UUI appears to be a distinct presentation with more specific contributory mechanisms than milder UUI.
Women who take hormone replacement therapy (HRT) to help alleviate symptoms of the menopause may have an increased risk of hearing loss, a study has found.WebMD Health News
Authors: Tanaka S, Hishiki M, Ogasawara J, Sorimachi E, Nakayama M Abstract Although most women with type 1 diabetes experience the normal transition to menopause, there is little information about the impact of hormone replacement therapy on their glycemic profiles. A 54-year-old postmenopausal woman with fulminant type 1 diabetes was admitted to our hospital due to diabetic ketoacidosis. She was treated with fluid replacement and a continuous insulin infusion. Thereafter, her glycemic profile was well maintained by daily multiple insulin injections. However, her glycemic profiles immediately deteriorated followin...
Postmenopausal women taking hormone-replacement therapy have gains in bone-mineral density, mass, and structure, which persist for up to 2 years after treatment stops.Medscape Medical News